Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revlimid + prednisone induction followed by Revlimid + melphalan + prednisone consolidation in elderly newly diagnosed multiple myeloma
2007-007616-28Phase 2Completed
- Sponsor
- Fondazione EMN Italy
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, melphalan and prednisone in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoints: Overall response rate (partial and complete response) and Safety of RP induction followed by MPR consolidation. Started Feb 2008; status: completed.
02
Drugs
lenalidomidemelphalanprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-007616-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007616-28.